7Drouin P,Standl E,Diamicron MR,Study Group.G1iclazide modified release:results of a 2-year study in patlentswith type 2 Diabetes[J].Diabetes Obes Wetab,2004,6(6):414.
3Peter P, Frank R, Nick G, et al. Sulfonylurea stimulation of in aulin secretion. Diabetes, 2002,51 ( Suppl 3): S368-S376.
4Garratt KN, Brady PA, Haasinger NL, et al. Sulfonylurea drugs increase early motality in patients with diabetes mellitus after direct angioplasty for acute myocardial infaction. J Am Cell Cardiol, 1999,33:119-124.
5Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev,2000,21:585-618.
6Davis TM, Parsons RW, Broadburst R J, et al. Arrhythmias and mortality after myocardial infaction in diabetic patients: relationship to diabetes treatment. Diabetes Care, 1998,21:637-640.
7Renstrom E, Barg S, Thevenod F, et al. Sul.fonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K + channel-independent action. Diabetes, 2002,51 (Suppl 1 ): S33-S36.
8Muller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic suffonylurea drug Amaryl. Mol Med, 2000,6:907-933.
9Dills DG, Schneider J. Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res, 1996,28:426-429.
10Muller G. Dynamics of plasma membrane microdomains and cross-talk to the insulin signalling cascade. FEBS Lett, 2002,531: 81-87.
6Ozbek M,Erdogan M. Preprandial repaglinide decreases exogenous insulin requirements and HbAl c levels in type 2 diabetlc patients taking intensive insulin treatment[J].ACTA DIABETOLOGICA,2006,(04):148.
7Rachek L I,Thomley N P,Grishko V 1. Protection ofINS-1 cells from free fatty acid induced apoptosis by targeting hOGG1 to mitochondria[J].Diabetes,2006,(04):1022.
8Kishore P,Tonelli J,Koppaka S. Timedependent effects of free fatty acids on glucose effectiveness in type 2 diabetes[J].Diabetes,2006,(06):1761.
9Betteridge DJ,Vergès B. Long-term effects on lipids and lipoproteins of pioglitazone versus gllclazide addition? to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes[J].Diabetologia,2005,(12):2477.
